Skip to main content
Top
Published in: Clinical Rheumatology 2/2009

01-02-2009 | Original Article

An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility

Authors: Chiara M. Antonioli, Giovanni Bua, Anna Frigè, Katia Prandini, Sara Radici, Mirko Scarsi, Elisabetta Danieli, Andrea Malvicini, Paolo Airo

Published in: Clinical Rheumatology | Issue 2/2009

Login to get access

Abstract

Few data are available to assess the efficacy of rehabilitative interventions in systemic sclerosis (SSc). We refer here the results of an individualized rehabilitation program in 16 patients with SSc. In particular, when possible, the number of patients who achieved a minimal clinically important difference (MCID) was determined. Results were evaluated taking advantage of the development of validated questionnaires and tests to assess quality of life (QOL) and disability in SSc. At the end of a period of 4 months of observation, 69% and 62% of patients reported an improvement of the physical and mental components of the SF-36 higher than the MCID (as established in other rheumatic conditions). Analogously, an improvement of the impact of respiratory disease on patients’ QOL, as assessed by the Saint George’s Respiratory Questionnaire, was perceived by 67% of them. These results might be explained by better exercise tolerance, which was suggested by the significant reduction of the heart rate and of a visual analogue scale for dyspnoea at the end of the 6-min walking test. Finally, a statistically significant improvement of hand mobility, as assessed by the hand mobility in scleroderma test was obtained. This study suggests that a significant proportion of patients with SSc experience an improvement in their perception of QOL, a better exercise tolerance, and a better hand mobility after a rehabilitation program consisting by a 2-week period of daily individual 30-min sessions as outpatient, followed by at-home exercise program.
Literature
1.
go back to reference Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557–567PubMedCrossRef Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557–567PubMedCrossRef
2.
go back to reference Seibold JR (2005) Scleroderma. In: Harris ED Jr, Budd RC, Firestein GS et al (eds) Kelley’s textbook of rheumatology. 7th edn. Elsevier, Philadelphia, pp 1279–1308 Seibold JR (2005) Scleroderma. In: Harris ED Jr, Budd RC, Firestein GS et al (eds) Kelley’s textbook of rheumatology. 7th edn. Elsevier, Philadelphia, pp 1279–1308
3.
go back to reference Khanna D, Ahmed M, Furst DE et al (2007) Health values of patients with systemic sclerosis. Arthritis Rheum 57:86–93PubMedCrossRef Khanna D, Ahmed M, Furst DE et al (2007) Health values of patients with systemic sclerosis. Arthritis Rheum 57:86–93PubMedCrossRef
4.
go back to reference Casale R, Buonocore M, Matucci-Cerinic M (1997) Systemic Sclerosis (Sclerodermia): an integrated challenge in rehabilitation. Arch Phys Med Rehabil 78:767–773PubMedCrossRef Casale R, Buonocore M, Matucci-Cerinic M (1997) Systemic Sclerosis (Sclerodermia): an integrated challenge in rehabilitation. Arch Phys Med Rehabil 78:767–773PubMedCrossRef
5.
go back to reference Mouthon L, Berezné A, Poiraudeau S, Guillevin L (2006) Therapeutic management of systemic sclerosis. Presse Med 35:1975–1982, [French]PubMedCrossRef Mouthon L, Berezné A, Poiraudeau S, Guillevin L (2006) Therapeutic management of systemic sclerosis. Presse Med 35:1975–1982, [French]PubMedCrossRef
6.
go back to reference Khanna D, Lovell DJ, Giannini E et al (2008) Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 67:703–709PubMedCrossRef Khanna D, Lovell DJ, Giannini E et al (2008) Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 67:703–709PubMedCrossRef
7.
go back to reference Hays RD, Woolley JM (2000) The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 18:419–423PubMedCrossRef Hays RD, Woolley JM (2000) The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 18:419–423PubMedCrossRef
8.
go back to reference LeRoy EC, Black C, Fleischmayer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–208PubMed LeRoy EC, Black C, Fleischmayer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–208PubMed
9.
go back to reference Airò P, Danieli E, Rossi M et al (2007) Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 25:293–296PubMed Airò P, Danieli E, Rossi M et al (2007) Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 25:293–296PubMed
10.
go back to reference Airò P, Rossi M, Scarsi M, Danieli E, Grottolo A, Zambruni A (2007) Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. Clin Exp Rheumatol 25:722–727PubMed Airò P, Rossi M, Scarsi M, Danieli E, Grottolo A, Zambruni A (2007) Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. Clin Exp Rheumatol 25:722–727PubMed
11.
go back to reference Poole JL, Steen VD (1991) The use of the Health Assessment Questionnaire to determine physical disability in systemic sclerosis. Arthritis Care Res 4:27–31PubMedCrossRef Poole JL, Steen VD (1991) The use of the Health Assessment Questionnaire to determine physical disability in systemic sclerosis. Arthritis Care Res 4:27–31PubMedCrossRef
12.
go back to reference Ranza R, Marchesoni A, Calori G et al (1993) The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 11:123–128PubMed Ranza R, Marchesoni A, Calori G et al (1993) The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 11:123–128PubMed
13.
go back to reference Khanna D, Furst DE, Hays RD et al (2006) Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 65:1325–1329PubMedCrossRef Khanna D, Furst DE, Hays RD et al (2006) Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 65:1325–1329PubMedCrossRef
14.
go back to reference Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef
15.
go back to reference Apolone G, Mosconi P (1998) The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036PubMedCrossRef Apolone G, Mosconi P (1998) The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036PubMedCrossRef
16.
go back to reference Cossutta R, Zeni S, Soldi A, Colombelli P, Belotti Masserini A, Fantini F (2002) Evaluation of quality of life in patients with systemic sclerosis by the SF-36 questionnaire. Reumatismo 54:122–127, [Italian]PubMed Cossutta R, Zeni S, Soldi A, Colombelli P, Belotti Masserini A, Fantini F (2002) Evaluation of quality of life in patients with systemic sclerosis by the SF-36 questionnaire. Reumatismo 54:122–127, [Italian]PubMed
17.
go back to reference Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr (2000) Determining minimally important changes in generic and disease- specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 7:1478–1487CrossRef Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr (2000) Determining minimally important changes in generic and disease- specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 7:1478–1487CrossRef
18.
go back to reference Beretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R (2007) Validity of the Saint George’s Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to Systemic Sclerosis. Rheumatology 46:296–301PubMedCrossRef Beretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R (2007) Validity of the Saint George’s Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to Systemic Sclerosis. Rheumatology 46:296–301PubMedCrossRef
19.
go back to reference Carone M, Bertolotti G, Anchisi F et al (1999) The St. George’s Respiratory Questionnaire (SGRQ): Italian version. Rassegna di Patologia dell’Apparato Respiratorio 14:31–37 Carone M, Bertolotti G, Anchisi F et al (1999) The St. George’s Respiratory Questionnaire (SGRQ): Italian version. Rassegna di Patologia dell’Apparato Respiratorio 14:31–37
20.
go back to reference Jones PW, Quirk FH, Baveystock CM (1991) The St George’s Respiratory Questionnaire. Respir Med 85:25–31PubMedCrossRef Jones PW, Quirk FH, Baveystock CM (1991) The St George’s Respiratory Questionnaire. Respir Med 85:25–31PubMedCrossRef
21.
go back to reference Sandqvist G, Eklund M (2000) Validity of HAMIS: A test of Hand Mobility in Scleroderma. Arthritis Care Res 13:382–387PubMedCrossRef Sandqvist G, Eklund M (2000) Validity of HAMIS: A test of Hand Mobility in Scleroderma. Arthritis Care Res 13:382–387PubMedCrossRef
22.
go back to reference American Thoracic Society (2002) Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117 American Thoracic Society (2002) Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117
23.
go back to reference Redelmeier DA, Bayoumi AM, Goldstein RS et al (1997) Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 155:1278–1282PubMed Redelmeier DA, Bayoumi AM, Goldstein RS et al (1997) Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 155:1278–1282PubMed
24.
go back to reference Mahler DA, Horowitz MB (1994) Perception of breathlessness during exercise in patients with respiratory disease. Med Sci Sports Exe 20:1078–1081 Mahler DA, Horowitz MB (1994) Perception of breathlessness during exercise in patients with respiratory disease. Med Sci Sports Exe 20:1078–1081
25.
go back to reference De Torres JP, Pinto-Plata V, Ingenito E et al (2002) Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 121:1092–1098PubMedCrossRef De Torres JP, Pinto-Plata V, Ingenito E et al (2002) Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 121:1092–1098PubMedCrossRef
26.
go back to reference Mahler DA, Horowitz MB (1994) Clinical evaluation of exertional dyspnea. Clin Chest Med 15:259–269PubMed Mahler DA, Horowitz MB (1994) Clinical evaluation of exertional dyspnea. Clin Chest Med 15:259–269PubMed
27.
go back to reference Cotes JE, Chinn DJ, Roca J, Quanjer PH, Yernault JC (1993) Standardization of the measurement of transfer factor (diffusing capacity). Eur Respir J (suppl) 16:41–52 Cotes JE, Chinn DJ, Roca J, Quanjer PH, Yernault JC (1993) Standardization of the measurement of transfer factor (diffusing capacity). Eur Respir J (suppl) 16:41–52
28.
go back to reference Quanjer PH, Tammerling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1994) Lung volumes and forced ventilatory flows. Rev Mal Respir 11:5–40PubMed Quanjer PH, Tammerling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1994) Lung volumes and forced ventilatory flows. Rev Mal Respir 11:5–40PubMed
29.
go back to reference Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1277–1280 Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1277–1280
30.
go back to reference Alexanderson H, Stenstrom CH, Jenner G, Lundberg I (2000) The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 29:295–301PubMedCrossRef Alexanderson H, Stenstrom CH, Jenner G, Lundberg I (2000) The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 29:295–301PubMedCrossRef
31.
go back to reference de Carvalho MRP, Sato EI, Tebexfreni AS et al (2005) Effects of a supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum 53:838–844PubMedCrossRef de Carvalho MRP, Sato EI, Tebexfreni AS et al (2005) Effects of a supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum 53:838–844PubMedCrossRef
32.
go back to reference Sandqvist G, Akesson A, Eklund M (2004) Evaluation of paraffin bath treatment in patients with systemic sclerosis. Disabil Rehabil 26:981–987PubMedCrossRef Sandqvist G, Akesson A, Eklund M (2004) Evaluation of paraffin bath treatment in patients with systemic sclerosis. Disabil Rehabil 26:981–987PubMedCrossRef
33.
go back to reference Naylor PW, Douglass CW, Mix E (1984) The nonsurgical treatment of microstomia in scleroderma: A pilot study. Oral Surg Oral Med Oral Pathol 57:508–511PubMedCrossRef Naylor PW, Douglass CW, Mix E (1984) The nonsurgical treatment of microstomia in scleroderma: A pilot study. Oral Surg Oral Med Oral Pathol 57:508–511PubMedCrossRef
34.
go back to reference Danieli E, Airò P, Bettoni L et al (2005) Health-Related quality of life measured by the short form 36 (SF-36) in Systemic Sclerosis: Correlations With indexes of Disease Activity and severity, disability, and depressive symptoms. Clin Reumatol 24:48–54CrossRef Danieli E, Airò P, Bettoni L et al (2005) Health-Related quality of life measured by the short form 36 (SF-36) in Systemic Sclerosis: Correlations With indexes of Disease Activity and severity, disability, and depressive symptoms. Clin Reumatol 24:48–54CrossRef
35.
go back to reference Airo’ P, Tabaglio E, Frassi M, Scarsi M, Danieli E, Rossi M (2007) Prevalence of systemic sclerosis in Valtrompia in northern Italy. A collaborative study of rheumatologists and general practitioners. Clin Exp Rheumatol 25:807–809 Airo’ P, Tabaglio E, Frassi M, Scarsi M, Danieli E, Rossi M (2007) Prevalence of systemic sclerosis in Valtrompia in northern Italy. A collaborative study of rheumatologists and general practitioners. Clin Exp Rheumatol 25:807–809
Metadata
Title
An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility
Authors
Chiara M. Antonioli
Giovanni Bua
Anna Frigè
Katia Prandini
Sara Radici
Mirko Scarsi
Elisabetta Danieli
Andrea Malvicini
Paolo Airo
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1006-x

Other articles of this Issue 2/2009

Clinical Rheumatology 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine